Bifulco Maurizio, Grimaldi Claudia, Gazzerro Patrizia, Pisanti Simona, Santoro Antonietta
Department of Pharmaceutical Sciences, University of Salerno, Fisciano, Salerno, Italy.
Mol Pharmacol. 2007 Jun;71(6):1445-56. doi: 10.1124/mol.106.033118. Epub 2007 Feb 27.
The advent of the highly selective cannabinoid receptor (CB1) antagonist, rimonabant (SR141716; Acomplia) can revolutionize the ability of the clinicians to manage obesity. Large-scale clinical trials have demonstrated that rimonabant therapy can reduce obesity. Although, the precise mechanisms of action of rimonabant have to be further dissected, it is emerging, from both preclinical and clinical research, that not only is rimonabant an antiobesity drug, but also its pleiotropic functions affect a broad range of diseases, from obesity-related comorbidities to drug dependence and cancer. Here we review recent data from the literature and discuss the full pharmacological potential of this drug.
高选择性大麻素受体（CB1）拮抗剂利莫那班（SR141716；Acomplia）的出现，可能会彻底改变临床医生治疗肥胖症的能力。大规模临床试验表明，利莫那班治疗可减轻肥胖。尽管利莫那班的确切作用机制还有待进一步剖析，但临床前和临床研究均显示，利莫那班不仅是一种抗肥胖药物，其多效性功能还会影响从肥胖相关合并症到药物依赖和癌症等多种疾病。在此，我们回顾文献中的最新数据，并探讨该药物的全部药理学潜力。
